Argenx's Vyvgart franchise addresses about 28,000 patients today, with the company targeting 60,000 by 2030. The biotech is solidly profitable, with Q3 revenue up 54% and $3.7 billion in cash to fund growth.
argenx's revenue expanded from roughly $790.7M in 2025Q1 to $3.2B in 2025Q4, and operating margin moved from -23.3% in 2024Q2 to 30.1% in 2026Q2, suggesting the VYVGART franchise has reached commercial scale with a gross margin steady near 88% to 90%.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue scaled several-fold while gross margin held between 88% and 90%, and operating margin recovered to 30.1% in 2026Q2 from negative levels in 2024, though the 46% sequential revenue decline into 2026Q4 warrants close monitoring of run-rate durability.
VYVGART generated over $4.1 billion in 2025, nearly doubling year-on-year, showcasing strong revenue growth.
New clinical data presented at the 2026 American Academy of Neurology meeting demonstrated VYVGART's efficacy in treating ocular myasthenia gravis and broader MG subtypes.
argenx SE operates in key international markets including the United States, Japan, China, and the Netherlands, enhancing its revenue potential.
Trailing total returns as of 11/13/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | $7.80+4.8% vs $7.44 | $2.8B+69.6% vs $1.7B |
Q2 2026 May 7, 2026 | $5.90+14.3% vs $5.16 | $3.2B+121.8% vs $1.4B |
Q1 2026 Feb 26, 2026 | $8.02+48.2% vs $5.41 | $2.4B+79.6% vs $1.3B |
Q4 2025 Oct 30, 2025 | $5.18+18.5% vs $4.37 | $948M-25.7% vs $1.3B |
Argenx's Vyvgart franchise addresses about 28,000 patients today, with the company targeting 60,000 by 2030. The biotech is solidly profitable, with Q3 revenue up 54% and $3.7 billion in cash to fund growth.
Argenx to acquire UNP for $550 million upfront plus contingent value rights tied to development and regulatory milestones, for total potential value of up to approximately $1.15 billion
Amsterdam, the Netherlands, November 9, 2026, 07:00 CET – argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced a definitive agreement to acquire Unnatural Products, Inc. (UNP), adding a macrocyclic peptide discovery engine to its immunology innovation capabilities. argenx, which already holds a minority stake in UNP, will acquire all remaining shares in a transaction valuing UNP at up to approximately $1.15 billion across upfront and milestone payments. This acquisition expands the ways argenx can pursue novel biology and develop oral or long-acting medicines for people living with serious immune-mediated diseases.
ALKIVIA met its primary and key secondary endpoints in the combined IMNM and DM population First Phase 3 study to demonstrate statistically significant and clinically meaningful benefit in IMNM, an autoimmune myositis subtype with no approved therapies Consistent, clinically meaningful treatment effect in DM, demonstrating improvements in muscle strength and skin disease activity November 7, 2026, 10:00 AM ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced that data from the Phase 3 ALKIVIA study demonstrating rapid and sustained improvement with VYVGART ® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in patients with autoimmune myositis will be featured in a late-breaking oral presentation (#LB24) at the American College of Rheumatology (ACR) Convergence 2026 on November 11, 2026, from 9:15-9:30 a.m. ET. Combined IMNM and DM population: Primary and key secondary endpoints met The study met its primary endpoint in the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) patient population, demonstrating that patients treated with efgartigimod achieved a statistically significant and clinically meaningful 15.4-point greater improvement in mean Total Improvement Score (TIS) at Week 52 versus placebo (p=0.0011; 48.0 vs 32.6).
Benchmark ARGX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for argenx SE (ARGX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $981.33 | $63.67B | 49.99 | 89.64% | 31.11% | 20.15% | — | |
| $16.27 | $1.6B | -3.17 | 20.13% | -71.78% | — | — | |
| $156.65 | $20.91B | 7.94 | 65.19% | 54.34% | 159.72% | — | |
| $16.01 | $1.69B | 114.93 | 15.58% | 0.75% | 1.04% | — | |
| $56.70 | $10.96B | -574.47 | 12.87% | -0.52% | -0.31% | — | |
| $27.31 | $4.54B | -8.00 | 33.87% | -64.64% | -110.84% | — |
argenx SE (ARGX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when ARGX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
argenx SE (ARGX) stock FAQ — growth, dividends, profitability & financials explained
argenx SE (ARGX) reported $4.15B in revenue in fiscal year 2025. That is 284775% more than the $1.5M of fiscal year 2011.
argenx SE (ARGX) grew revenue by 89.6% in fiscal year 2025, compared with the prior fiscal year.
Yes. argenx SE (ARGX) earned $1.29B in net income in fiscal year 2025 (a 31.1% net margin).
argenx SE (ARGX) had a return on equity (ROE) of 20.2% in fiscal year 2025. That is well above the market's typical 10-15%.
argenx SE (ARGX) generated $844.3M in free cash flow in fiscal year 2025.